Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Workload At FDA: Policy Development Far Exceeds Application Review

Executive Summary

Even as applications themselves remain low burden, intense policy efforts put pressure on user fees.

You may also be interested in...



Biosimilar User Fee Negotiations Won't Start Until 2016

Mid-December kick-off meeting puts emerging user fee program on much later track than others.

Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested

New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.

How To Get A Meeting With FDA: Guidance Describes Formal Meetings For Biosimilars

FDA’s fourth biosimilars-related guidance describes the formal meeting process for sponsors with products in development; the process will require extensive requests and information packages.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel